Clinical Trial: Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: CLINICAL TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF RAPAMYCIN IN ANGIOMYOLIPOMAS IN PATIENTS WITH TUBEROUS SCLEROSIS
Brief Summary: The purpose of this study is to determine whether rapamycin is safe and effective in the treatment of renal angiomyolipomas in patients with tuberousclerosis.
Detailed Summary:
Sponsor: Fundacio Puigvert
Current Primary Outcome: Angiomyolipoma volume [ Time Frame: 2 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome: skin lesions, AML complications, [ Time Frame: 2 years ]
Original Secondary Outcome: Same as current
Information By: Fundacio Puigvert
Dates:
Date Received: October 6, 2010
Date Started: October 2008
Date Completion:
Last Updated: March 7, 2012
Last Verified: March 2012